
Latigo Biotherapeutics (NASDAQ:LTGO) reported quarterly losses of $(27.59) per share. This is a 24.45 percent increase over losses of $(36.52) per share from...
You can purchase shares of Latigo Biotherapeutics (NASDAQ:LTGO) through any online brokerage.
Other companies in Latigo Biotherapeutics’s space includes: Eli Lilly and Co (NYSE:LLY), Johnson & Johnson (NYSE:JNJ), Merck & Co Inc (NYSE:MRK), Novartis AG (NYSE:NVS) and AstraZeneca PLC (NYSE:AZN).
Latigo Biotherapeutics has a consensus price target of $45.33.
The stock price for Latigo Biotherapeutics (NASDAQ: LTGO) is $16.57 last updated October 22, 2026 at 4:00 PM EDT.
There are no upcoming dividends for Latigo Biotherapeutics.
Latigo Biotherapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Latigo Biotherapeutics.
Latigo Biotherapeutics is in the Health Care sector and Pharmaceuticals industry. They are listed on the NASDAQ.
Latigo Biotherapeutics Inc is a clinical-stage biotechnology company focused on developing non-opioid pain medicines designed to rapidly and effectively stop the transmission of pain without the risk of addiction. Its flagship product candidates,...